Oncolytics Biotech Inc. Message Board

Cantech Letter
Oncolytics Biotech soars after Reolysin trial proves 95% effective
February 8, 2013 By Cantech
Oncolytics Biotech (TSX:ONC) The company announced that a Phase Two study showed its Reolysin treatment was 95% effective in treating tumours.
The trial consisted of 20 patients who had squamous cell carcinoma of the lung. They were given intravenous administration of Reolysin in combination with carboplatin and paclitaxel. 19 of them exhibited overall tumour shrinkage.
Oncolytics Biotech CEO Dr. Brad Thompson said the results were more than encouraging.
“It’s exciting to have 95 per cent of patients in this study exhibit tumour shrinkage, and these results further suggest that Reolysin may have potential use in neoadjuvant (presurgical) settings,” he said. “Based on these findings, we intend to continue to look at Reolysin as a treatment for cancers of the lung and cancers that metastasize to the lung.”